异舒吉对肺心病急性加重期即时血液动力学影响的研究

目的 :研究异舒吉对肺心病急性加重期即时血液动力学的影响。方法 :通过对 10例诊断为慢性肺源性心脏病患者给予异舒吉静脉注射 ,并通过三腔Swan -Ganz监测用药前后的血液动力学参数及检测动脉血气 ,所得数值进行统计学处理。结果 :用药前后心率无明显改变 (P >0 .0 5 ) ,右房压下降 4 1% (P <0 .0 0 1) ,平均肺动脉压降低 2 8% (P <0 .0 0 1) ,心输出量增加 4 3% (P <0 .0 0 1) ,肺血管阻力降低 5 5 % (P <0 .0 0 1) ,体循环阻力降低 4 4% (P <0 .0 0 1) ,平均动脉压下降 7% (P >0 .0 5 )。对动脉血气 pH、PaO2 、PaCO2 、SaO2 均无显著影响 (P >0 .0 5 )。结论 :异舒吉对肺心病急性加重期的血液动力学产生有益的影响 ,能显著地改善右心室前后负荷 ,降低肺动脉压 ,改善右室功能。对动脉血气无显著影响 ,对体循环压力有轻度影响 ,但未达到统计学意义。因此 ,异舒吉在肺心病急性加重期的应用是有效和安全的。     

阿托伐他汀治疗非缺血性心脏病慢性心衰患者的疗效观察

目的:本文评价阿托伐他汀对非缺血性心脏病患者心力衰竭的疗效.方法:将86例非缺血性心脏病合并慢性心衰患者随机分为2组,对照组(常规治疗组n=43)服用β受体阻滞荆 ACEI 利尿剂,治疗组(n=43)在对照组治疗的基础上加服阿托伐他汀(10mg/d),随访1年.结果:合用阿托伐他汀能明显改善心功能.提高EF,缩小左室舒张末内径.结论:阿托伐他汀联合神经内分泌拮抗荆能提高非缺血性心脏病合并慢性心衰的治疗效果.     

单硝酸异山梨酯联合卡托普利治疗老年慢性肺源性心脏病心力衰竭临床观察

目的:观察单硝酸异山梨酯联合卡托普利治疗老年慢性肺源性心脏病(肺心病)心力衰竭的疗效.方法:126例老年肺心病患者随机分为两组,对照组63例,治疗组63例.治疗组除常规治疗外,同时加用单硝酸异山梨酯片20～40mg,1次/d口服、卡托普利片每次6.25～12.5mg,3次/d口服,7d后对两组临床治疗效果进行评价.结果:治疗组总有效率为98.4%,对照组总有效率为76.2%,两组比较差异有显著性(P<0.05).结论:单硝酸异山梨酯联合卡托普利可提高老年肺心病心力衰竭病人的疗效.     

复方丹参滴丸治疗早期糖尿病性视网膜病变的临床研究

目的：观察复方丹参滴丸对早期糖尿病性视网膜病变的治疗效果。方法：收集Ⅰ～Ⅲ期糖尿病视网膜病变患者107例，其中治疗组50例，对照组57例。治疗组服用复方丹参滴丸10粒／次，3次／d，对照组服用维生素B120mg／次、维生素C0．2g／次、维生素E0．1g／次、肌苷片0．2g／次，3次／d，连续用药6个月。观察治疗前后患者视力、视野及跟底血管造影的变化情况。结果：治疗组服药半年后与治疗前相比视力明显提高，P〈0．01；视野灰度值（MD）降低，P〈0．01；眼底微动脉瘤及出血斑数量减少，P〈0．01；两组间治疗后结果比较差异显著。结论：复方丹参滴丸对早期糖尿病性视网膜病变有明显的治疗作用，较传统复合维生素治疗效果有明显提高。     

硫酸镁治疗胎儿宫内生长迟缓15例临床分析

目的 :探讨硫酸镁治疗胎儿宫内生长迟缓 (IUGR)的临床意义。方法 :对 4 5例IUGR孕妇随机分为治疗 1组、治疗 2组、未治疗组各 15例 ,并以同期分娩的 15例正常孕妇为对照组。治疗 1组用复方氨基酸 2 5 0ml、10 %葡萄糖 5 0 0ml+辅酶A10 0U、三磷酸腺苷 4 0mg、维生素C 2g ,静脉滴注 ,每日 1次共 10d ,口服硫酸锌 2片 ,一日三次 ;治疗 2组在治疗 1组的基础上再加 10 %葡萄糖 5 0 0ml+2 5 %硫酸镁 2 0ml,静脉滴注 ,4h内均匀滴完 ,每日 1次共 10d。结果 :新生儿体重比较 ,治疗 2组与对照组差异无显著性 (P <0 .0 5 )。胎盘的重量比较 ,对照组均重于IUGR各组 ,治疗 2组重于未治疗组和治疗 1组 ,差异有极显著性 (P <0 .0 1)。结论 :硫酸镁治疗IUGR能明显改善子宫胎盘血流灌注 ,促进胎儿生长发育。     

BiPAP呼吸机无创机械通气治疗COPD伴Ⅱ型呼衰的探讨

目的探讨双水平正压无创通气（BiPAP）对慢性阻塞性肺疾病（COPD）病人合并Ⅱ型呼吸衰竭的治疗价值。方法78例COPD病人合并Ⅱ型呼吸衰竭患者随机分成二组，治疗组38例和对照组40例，对照组给予常规抗感染、平喘、祛痰和低浓度氧疗，治疗组除了常规治疗外，加无创机械通气（BiPAP）治疗，比较两组患者治疗前后血气的变化，对结果进行统计学处理。结果治疗组治疗后动脉血气PaO2、SaO2逐渐上升，PaCO2值下降，与治疗前相比，有极显著性差异，P〈0．01。对照组治疗后动脉血气PaO2、SaO2逐渐上升，PaCO2值下降，与治疗前相比，有显著性差异，P〈0．05。比较两组治疗前后动脉血PaCO2下降幅度差，PaO2、SaO2上升幅度差，有显著性差异，P〈0．05。结论本法治疗COPD病人合并Ⅱ型呼吸衰竭有肯定疗效。     

复方丹参注射液的临床应用

1　治疗冠心病心绞痛居氏报道 :治疗组 5 1例 ,男 39例 ,女 12例 ,年龄4 8～ 73岁 ,平均年龄 61岁 ,对照组 32例 ,男 2 5例 ,女7例 ,年龄 4 7～ 68岁 ,平均年龄 5 7岁。治疗组 :临床应用复方丹参注射液 (上海第一生化药业公司上海第一制药厂生产 )。每支 2ｍｌ相当于丹参 2 ｇ ,根据患者的不同发病情况 ,选用 8～ 2 0ｍｌ,复方丹参注射液 ,加用 5 %葡萄糖注射液 5 0 0ｍｌ稀释后静滴 ,每日一次 ,14ｄ为 1疗程。对照组 :服用消心痛 10ｍｌ,每日 3次 ,静脉滴注极化液 14ｄ。结果 :两组治疗后心绞痛显著减轻 ,所需平均天数治疗组为 3.5± 8.9ｄ…     

复方丹参滴丸治疗心绞痛疗效观察

冠心病心绞痛是中、老年常见病及急症之一。我们自 1999～ 2 0 0 1年对 30例冠心病心绞痛患者采用口服复方丹参滴丸治疗 ,观察其治疗效果 ,现报道如下。1　资料与方法1.1　一般资料　按 1979年ＷＨＯ命名的缺血性心脏病的诊断标准 ,选择反复发作心绞痛 ,心电图ＳＴ—Ｔ改变的 5 4例患者 ,随机分为复方丹参滴丸治疗组 30例 ,对照组 2 4例 ;平均年龄 5 6岁 (5 2～ 78) ;治疗组与对照组从性别、发病病情、既往病史、病程长短及各种药物治疗情况均无明显差异。1.2　方法　治疗组口服复方丹参滴丸 (天津天士力制药集团有限公司生产 ) 3次 /ｄ ,每…     

冠心宁、银杏叶注射液治疗冠心病心绞痛疗效观察

目的:观察冠心宁、银杏叶注射液治疗冠心病心绞痛的疗效.方法:治疗组52例予冠心宁注射液、银杏叶注射液各10ml,每日一次静脉滴注,疗程2周,其它治疗方法与对照组50例相同.分别观察主要症状、体征变化,记录心绞痛发作次数,监测心电图、血粘度变化.结果:治疗组心绞痛、心电图总有效率(94.0%、88.0%)与对照组有效率(70.0%、68.0%)比较有显著性差异(P＜0.05),治疗组的血粘度的降低明显优于对照组(P＜0.05).结论:冠心宁、银杏叶注射液治疗冠心病心绞痛疗效确切.     

中西医结合治疗老年性肾病的疗效观察

目的:观察中西医结合治疗老年性肾病慢性肾功能不全早、中期的治疗疗效.方法:47例病人随机分为两组,治疗组24例采用中医药辩证治疗加常规西药治疗;对照组采用保肾康3片,爱西特8片各一日三次口服,观察治疗结果并进行比较.结果:治疗组总有效率91.7%,对照组总有效率73.9%,两组经统计学比较有显著性差异(P<0.05).结论:中西医结合治疗老年性慢性肾病其疗效明显,值得推广.     

A case study of imported pulmonary coccidioidomycosis

Coccidioidomycosis is an endemic disease of the Western hemisphere. The cases in non-endemic areas are mostly imported. Determining a history of exposure is critical for performing the diagnosis of coccidioidomycosis, especially for cases occurring in a non-endemic area. In this study, a 71-year-old Chinese male presented to our hospital with chronic cough and malaise, and was found to have a mass in the middle lobe of right lung. He had been visiting Arizona, USA for four months before admission. Pulmonary coccidioidomycosis was confirmed by the results of histopathological examination after lobectomy. Typical microscopic features of Coccidioides are definitely diagnostic, but need be differentiated from other budding yeast infection or carcinoma histopathologically.     

游泳运动员肺功能异常的简要分析

文章旨在实际调查研究的基础上,比较了不同训练阶段优秀游泳运动员肺功能的差异,探讨相关炎症因子与肺功能改变的关系,并初步研究激发方式对气道反应性的影响.     

Concurrent pulmonary thrombosis with systemic embolism: a case report

Based on different mechanisms of blood coagulation, coexistence of venous thromboembolism and arterial thrombosis in a single individual is extremely rare in clinical practice. Both antiplatelet and anticoagulation therapy should be adopted for patients with arteriovenous embolism. Balancing the risk of ischemia and hemorrhage is especially challenging in these patients in order to achieve an optimal clinical benefit. We report on a 55-year-old female with acute pulmonary embolism (PE), subsequently diagnosed as having acute myocardial infarction (AMI) and a cerebral infarction. Examinations had been carried out, excluding potential arteriovenous shunts, cancer, antiphospholipid syndrome and other common hypercoagulable states. A combination of an anticoagulant drug (rivaroxaban, an Xa inhibitor) and an antiplatelet agent (clopidogrel, an ADP receptor inhibitor) was prescribed with a β-blocker and atorvastatin. The embolus was gradually shrunk during the next 10 months, and then it turned back into expanding. During the 16 months’ follow-up, an aneurysm of left ventricular apex was found through an echocardiogram and an angiotensin-converting enzyme inhibitor was administered. We conclude that combined anticoagulation and antiplatelet therapy significantly relieved the symptoms and improved the prognosis in patients suffering from arteriovenous embolism without any major clinical bleeding events.     

Molecular hydrogen is a promising therapeutic agent for pulmonary disease

Molecular hydrogen exerts biological effects on nearly all organs. It has anti-oxidative, anti-inflammatory, and anti-aging effects and contributes to the regulation of autophagy and cell death. As the primary organ for gas exchange, the lungs are constantly exposed to various harmful environmental irritants. Short- or long-term exposure to these harmful substances often results in lung injury, causing respiratory and lung diseases. Acute and chronic respiratory diseases have high rates of morbidity and mortality and have become a major public health concern worldwide. For example, coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global pandemic. An increasing number of studies have revealed that hydrogen may protect the lungs from diverse diseases, including acute lung injury, chronic obstructive pulmonary disease, asthma, lung cancer, pulmonary arterial hypertension, and pulmonary fibrosis. In this review, we highlight the multiple functions of hydrogen and the mechanisms underlying its protective effects in various lung diseases, with a focus on its roles in disease pathogenesis and clinical significance.     

肺结核X线诊断分类500例探讨

目的旨在明确肺结核X线分类中两型合并的分类.方法本文收集经临床、肺结核细菌学和常规胸片确诊的肺结核500例,进行X线分类的探讨.结果X线分类,原发型167例,合并胸膜炎的6例;血型播散型70例,合并胸膜炎22例;继发型306例,合并胸膜炎74例.Ⅰ～Ⅲ型肺结核合并胸膜炎102例,占总病例数的20.4%.结论依据病因、发病机理、中国结核病分类法(1998),按原发型肺结核合并结核性胸膜炎、血行散型肺结核合并结核性胸膜炎、继发型肺结核合并结核性胸膜炎,进行X线分型.     

Ultrasound ablation of pulmonary veins for treatment of paroxysmal atrial fibrillation

INTRODUCTIONMostparoxysmalatrialfibrillationisactivatedbyatrialectopiesoriginatinginthepulmonaryveins.Severalresearchesdemonstratedthatal most 50 %offocalatrialfibrillationoriginatesintheleftsuperiorpulmonaryveinandabout3 0 %intherightsuperiorpulmonaryvei…     

铜陵市2011—2015年肺结核病疫情分析

目的:通过对铜陵市各区县2011~2015年肺结核病疫情的分析,为制订防治策略提供依据。方法:对2011~2015年疫情报告资料进行描述性流行病学分析。结果:从2011~2015年肺结核发病率的报告来看,发病率有所下降,2011年发病率是97.38/10万,到了2015年发病率是82.22/10万;男女比例为2.45:1;发病年龄主要分布在中老年群体。结论:全区结核病预防和治理工作取得了一定成效,从2011~2015年肺结核发病率来看,发病率有所下降,2011年的97.38/10万下降到2015年的82.22/10万;作为工业城市,结核病是工作防治重点是企业工人和退休人员。     

VEGFmRNA and eNOSmRNA expression in immature rabbits with bleomycin-induced pulmonary hypertension

Objective: To investigate the evolution of pulmonary hypertension, the pathological changes of pulmonaryarteries, and the expression of VEGFmRNA and eNOSmRNA of pulmonary arterial endothelial cells in immature rabbitstreated with intratracheal bleomycin (BLM). Methods: Immature rabbits were divided into control and BLM group. Twoand four weeks after intratracheal normal saline or BLM injection, the systolic, diastolic and mean pulmonary arterypressure (PASP, PADP, MPAP) were measured by micro-catheter; the pathological changes and the expression ofVEGFmRNA and eNOSmRNA of endothelial cells in pulmonary arteries were evaluated by HE and in situ hybridization.Results: Two and four weeks after intratracheal injection of BLM, the PASP, PADP and MPAP increased 53%, 49%, 52%in 2 weeks, and 43%, 89%, 56% in 4 weeks; the wall thickness increased and the cavity in middle and small pulmonaryarteries became narrow; the Thickness Index (TI) and Area Index (AI) increased 25%, 14% in 2 weeks, and 22%, 24% in 4weeks; the level of VEGFmRNA and eNOSmRNA expression decreased 46%, 43% in 2 weeks, and 43%, 51% in 4 weeks.There was no significant difference between 2 weeks and 4 weeks BLM groups. Conclusion: The pulmonary artery pressurewas elevated, the thickness of wall increased and the cavity became narrow in middle and small pulmonary arteries, and thelevel of VEGFmRNA and eNOSmRNA expression in pulmonary arterial endothelial cells decreased in immature rabbitsafter 2 weeks and 4 weeks of intratracheal 4 U/kg BLM injection.     

Ultrasound ablation of pulmonary veins for treatment of paroxysmal atrial fibrillation

Objective: to evaluate the efficacy and safety of ultrasound ablation of pulmonary veins for treatment of paroxysmal atrial fibrillation. Methods: The study population consisted of 9 patients with 5 males and 4 females enrolled consecutively who had idiopathic paroxysmal atrial fibrillation(AF). The ultrasound balloon was positioned through a special sheath to the orifice of the target vein by a transseptal procedure. The balloon was inflated with contrast-mixed saline (contrast: saline = 1:4) whose volume was decided by the diameter of the target pulmonary vein. The ablation energy was usually set up at 35 to 40 watts with temperature controlled at 60℃. The duration of each ablation was about 120 seconds which was repeated not over 10 times. Results: The average duration of the total procedure was 132±68 min for our patients. The average fluoroscopy time was 33±17 min. With a mean follow-up of 16±8 months after the procedure, AF was completely eliminated in 4 patients without antiarrhythmic drugs. The episodes of atrial fibrillation were eliminated in 2 patients with low dosage of oral amiodarone (0.1, once daily) which was ineffective before the procedure. The frequency of episodes was similar to that before the procedure in 3 patients. There were no complications such as hemopericardium, air embolism and stenosis of the pulmonary veins by angiography, related to the procedure. Conclusion: Ultrasound ablation of the pulmonary veins is a new approach to treat paroxysmal atrial fibrillation. Before we determined its value, we need to do more researches with bigger sample, randomization and comparison design.